Bristol-Myers Squibb Company

BMS provided 2026 guidance of $46.0-$47.5 billion, a step-down from FY2025's $48.2 billion, reflecting the predictable but structurally adverse trajectory of the legacy portfolio. Individual product decline curves for Eliquis, Revlimid, and Opdivo are reasonably foreseeable given known patent calendars, but whether the Growth Portfolio offsets losses on schedule remains uncertain.

BMS operates across oncology, hematology, cardiovascular, immunology, and neuroscience, with Eliquis as the largest single product at roughly one-fifth of FY2025 revenues and no other product materially larger. The five-area therapeutic spread provides moderate single-product resilience, though oncology and hematology together account for the majority of the portfolio.

The United States accounts for the substantial majority of revenues, with international markets contributing a secondary share across Europe, Japan, and emerging markets. This US-heavy mix amplifies exposure to domestic policy changes, particularly the IRA's Medicare Drug Price Negotiation provisions already affecting Eliquis and targeting Opdivo for 2028.

Gross margins are guided at 69-70% for FY2026, reflecting favorable specialty drug pricing while patents hold, but the R&D cost base has been ramped to roughly $10 billion annually and CAR-T cell therapy manufacturing for Breyanzi and Abecma is capital-intensive with limited economies of scale at current volumes. The $2 billion strategic productivity initiative is delivering savings, yet total operating expenses remain guided at roughly $16.3 billion in 2026, keeping structural operating leverage constrained.

The majority of revenue derives from specialty drugs treating serious or life-threatening conditions (anticoagulation for atrial fibrillation, checkpoint inhibitor oncology, multiple myeloma), where discontinuation risk is low once a patient is established on therapy. The per-prescription/infusion model lacks contractual recurring visibility but benefits from high-inertia, repeat-demand dynamics across predominantly chronic and ongoing treatment regimens.